Please login to the form below

Not currently logged in
Email:
Password:

phase 2 trial

This page shows the latest phase 2 trial news and features for those working in and with pharma, biotech and healthcare.

Positive COPD data for Synairgen's SNG001 supports COVID-19 programme

Positive COPD data for Synairgen's SNG001 supports COVID-19 programme

Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... placebo. SNG001 delivers an inhaled formulation of

Latest news

More from news
Approximately 0 fully matching, plus 197 partially matching documents found.

Latest Intelligence

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... With the latest phase 2 data,

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    To win approval for public use, a larger phase 2 trial is need, which Moderna says is already in the planning stages and could start within a few months. ... The EMA has acknowledged the impact the pandemic may have on clinical trails and trial

  • Rethinking trials: the pros and cons of protocol amendments Rethinking trials: the pros and cons of protocol amendments

    AstraZeneca spokesman Matthew Kent said: “The BICLA was chosen as the primary endpoint for TULIP 2, following a full evaluation of the previous phase e trial TULIP 1, which did not ... The patient sampling size increases, as well, increasing the

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    MyoKardia is gathering PROs in its phase 2 hypertrophic cardiomyopathy trial. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    In phase 2, the figure fell to less than one-third. Data on the early-stage pipeline is lacking but anecdotal evidence suggests it is more diverse still. ... AbbVie is testing its anti-tau antibody ABBV-8E12 in a phase 2 trial, while Biogen has links to

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics